| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Astria Therapeutics, Inc. | Chief Legal Officer | Stock Option (Right to Buy) | 262,500 | 21 Mar 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ATXS | Astria Therapeutics, Inc. | 21 Mar 2025 | 1 | $0 | 4 | Chief Legal Officer | 25 Mar 2025, 16:06 |
| ATXS | Astria Therapeutics, Inc. | 08 Feb 2024 | 1 | $0 | 4 | Chief Legal Officer | 12 Feb 2024, 16:05 |
| ATXS | Astria Therapeutics, Inc. | 02 Jun 2023 | 1 | $0 | 4 | Chief Legal Officer | 06 Jun 2023, 08:07 |
| ATXS | Astria Therapeutics, Inc. | 01 Mar 2022 | 1 | $0 | 4 | Chief Legal Officer | 03 Mar 2022, 18:21 |
| ATXS | CATABASIS PHARMACEUTICALS INC | 08 Jun 2021 | 1 | $0 | 4 | Chief Legal Officer | 10 Jun 2021, 16:06 |
| ATXS | CATABASIS PHARMACEUTICALS INC | 02 Jun 2021 | 1 | $0 | 4 | Senior VP, General Counsel | 02 Jun 2021, 19:13 |